ReviewActa pharmaceutica Sinica. B2026
Where and when to strike: Spatiotemporally controlled smart nanomedicines for precision antibacterial therapy.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise of antimicrobial resistance calls for new therapeutic approaches that move beyond conventional broad-spectrum antibiotics toward precision-guided nanotherapeutics. This review examines how smart antibacterial nanomedicines achieve better therapeutic outcomes through two key control dimensions: Spatial precision (where) and temporal activation (when). We first discuss active targeting strategies that direct therapeutic payloads to infection sites while sparing healthy tissues. We then analyze microenvironment-responsive mechanisms that keep therapeutic agents inactive until they encounter specific pathological signals. Moving beyond a simple catalog of material properties, we propose a "Hierarchical Intelligence Framework" that organizes nanoparticles along a spectrum of increasing complexity-from basic ligand-guided systems to integrated, logic-responsive nanodevices operating through "Target-Trigger-Treat" protocols. By examining design principles and practical challenges in pharmaceutical development, this work outlines a path toward resistance-overcoming nanomedicines that may reshape infection management in the coming decades.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.